- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01931293
HLA-DRB1 and HLA-DQB1 Genotyping for Autoantibody-positive and -Negative Patients With Atrophic Glossitis or Burning Mouth Syndrome
January 28, 2016 updated by: National Taiwan University Hospital
Patients with atrophic glossitis (AG) or burning mouth syndrome (BMS) are frequently encountered in the oral mucosal disease clinic.
Our previous studies found a significantly higher frequency (26.7%) of serum gastric parietal cell antibody (GPCA) and a significantly higher frequency (31%) of serum thyroglobulin antibody (TGA) or thyroid microsomal antibody (TMA) in AG patients than in healthy control subjects.
Moreover, there is also a significantly higher frequency (13.3%) of serum GPCA or a significantly higher frequency (23.5%) of serum TGA or TMA in BMS patients than in healthy control subjects.
Because patients with one organ-specific autoantibody are prone to have another organ-specific autoantibody in sera, we also evaluated whether AG or BMS patients with GPCA are prone to have TGA or TMA in sera and vice versa.
We further found that 25.3% of TGA- or TMA-positive AG or BMS patients also have GPCA, 32.3% GPCA-positive AG or BMS patients also have TGA, and 30.6%
GPCA-positive AG or BMS patients also have TMA in their sera.
Without proper diagnosis and treatment, patients with GPCA are more likely to develop autoimmune atrophic gastritis and subsequently progress to gastric carcinoma, and patients with TGA or TMA may develop autoimmune thyroid disease and finally result in thyroid dysfunction.
In addition, previous studies have shown a close association of the HLA-DR or HLA-DQ loci with the presence of autoantibodies (such as GPCA, TGA or TMA) in patients with different types of autoimmune disease.
Therefore, in the following 3-year research project, we plan to collect 300 AG and 450 BMS patients from the oral mucosal disease clinic of Department of Dentistry, National Taiwan University Hospital.
For each year, 100 AG and 150 BMS patients are collected.
A 10-cc blood sample will be drawn from each patient, with 5 cc being used for the determination of the serum levels of GPCA, TGA and TMA and another 5 cc being used for the HLA-DRB1 and HLA-DQB1-genotyping using the polymerase chain reaction with sequence-specific primer (PCR-SSP) typing technique.
At the end of this 3-year study, we will realize the frequencies of presence of GPCA, TGA and TMA in sera of our 300 AG or 450 BMS patients.
After statistical analyses, we will also know which specific HLA-DRB1 or HLA-DQB1 allele and which specific DRB1-DQB1 haplotype are responsible for the possession of GPCA, TGA or TMA in sera of our AG or BMS patients.
In addition, we will understand which specific HLA-DRB1 or HLA-DQB1 allele and which specific DRB1-DQB1 haplotype are responsible for the possession of GPCA in TGA- or TMA-positive AG or BMS patients as well as for the possession of TGA or TMA in GPCA-positive AG or BMS patients.
With this important information in mind, we can predict the development of the specific autoimmune diseases such as autoimmune atrophic gastritis and autoimmune thyroid diseases and then adopt proper early diagnosis and treatment to prevent the future occurrence of these diseases and their potential complications (such as gastric carcinoma or thyroid dysfunction).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
750
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Andy Sun
- Phone Number: 67723 +8862-23123456
- Email: andysun7702@yahoo.com.tw
Study Locations
-
-
Test2
-
Taipei, Test2, Taiwan, test3
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Andy Sun, Professor
- Phone Number: 67702 +886-2-23123456
- Email: andysun7702@yahoo.com.tw
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinical diagnosis of atrophic glossitis or burning mouth syndrome.
- Patient's age is between 20 and 80 years.
Exclusion Criteria:
- An expectant mother or patients without atrophic glossitis or burning mouth syndrome.
- Patients have atrophic glossitis or burning mouth syndrome but refuse to take blood sample.
- Betel guid chewers or heavy alcohol drinkers, patients with autoimmune disease, stroke, liver or kidney dysfunction, or cardiovascular disaeses.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HLA-DR and DQ antigens
Isolation of patient's lymphocytes from 10 cc of blood to determine the HLA-DR and DQ antigens at the first visit.
|
Vitamin Supplement therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with finding the HLA-DRB1 and HLA-DQB1
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with finding the HLA-DRB1-DQB1 haplotype
Time Frame: 3 years
|
3 years
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with finding the presence of serum GPCA, TGA and TMA
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Andy Sun, Professor, No Organizatioinal Affiliation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2013
Primary Completion (Anticipated)
July 1, 2016
Study Completion (Anticipated)
July 1, 2016
Study Registration Dates
First Submitted
June 10, 2013
First Submitted That Met QC Criteria
August 26, 2013
First Posted (Estimate)
August 29, 2013
Study Record Updates
Last Update Posted (Estimate)
February 1, 2016
Last Update Submitted That Met QC Criteria
January 28, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201212066RIND
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrophic Glossitis, Burning Mouth Syndrome
-
University Hospital, ToursCompletedPrimary Burning Mouth SyndromeFrance
-
University of FloridaCompletedBurning Mouth Syndrome | Burning MouthUnited States
-
mariam hamoudaCompletedBenign Migratory GlossitisEgypt
-
Chang Gung Memorial HospitalMinistry of Science and Technology, TaiwanUnknownBurning Mouth SyndromeTaiwan
-
Universidad Nacional Autonoma de MexicoUnknownBurning Mouth SyndromeMexico
-
Federico II UniversityRecruitingBurning Mouth SyndromeItaly
-
University of CataniaCompleted
-
Universidad de MurciaCompleted
-
Presidio Ospedaliero Garibaldi-CentroUniversity of Padova; University of Catania; Carlo Besta Neurological InstituteCompletedBurning Mouth Syndrome
-
University of ZagrebCompletedMelatonin | Burning Mouth SyndromeCroatia
Clinical Trials on Supplementation of vitamin B complex, C, B12, folic acid, Iron and Zinic
-
Wageningen UniversityZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedCognitive Decline | Cognitive SymptomsNetherlands
-
University of Sao PauloNot yet recruitingObesity | Lupus ErythematosusBrazil
-
Istituto Ortopedico GaleazziCompletedAnemia | Orthopedic Disorder | Knee Arthropathy | Hip Arthropathy | Iron Poor BloodItaly
-
Azienda Ospedaliera Universitaria Integrata VeronaRecruiting
-
Poznan University of Life SciencesCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedBone Marrow DonorsItaly
-
Mundipharma (China) Pharmaceutical Co. LtdCompletedRefractory Peripheral T-Cell Lymphoma | Relapsed T-Cell LymphomaChina
-
Indian Council of Medical ResearchDelhi UniversityUnknown
-
Moshe FlugelmanTerminatedB12 Deficiency Combined With C677T Mutation on MTHFR GeneIsrael
-
Aristotle University Of ThessalonikiUniversity of Sheffield; University Hospital TuebingenCompletedDiabetes Mellitus | Diabetic Foot | Diabetic Neuropathies | Diabetic ComplicationGreece